NASDAQ · Financial Statements
Inozyme Pharma, Inc. (INZY) Financial Statements
$4.00
NASDAQ: INZY
Market Cap $258.25M
Overview Financials Dividend Inozyme Pharma, Inc. most recently reported annual revenue of $0, net profit of $-102.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2020 2021 2022 2023 2024 Revenue $0 $0 $0 $0 $0 Operating Profit $-57.0M $-57.0M $-69.0M $-76.0M $-104.0M Net Profit $-56.0M $-56.0M $-65.0M $-71.0M $-102.0M EPS $-2.39 $-2.39 $-1.73 $-1.37 $-1.62 Op Margin — — — — —
Balance Sheet (USD)
Metric 2020 2021 2022 2023 2024 Total Assets $169.0M $124.0M $139.0M $201.0M $123.0M Total Liabilities $11.0M $14.0M $21.0M $60.0M $65.0M Cash $160.0M $23.0M $33.0M $35.0M $21.0M Borrowings $1.0M $3.0M $7.0M $47.0M $47.0M
Cash Flow (USD)
Metric 2020 2021 2022 2023 2024 Operating Cash Flow $-36.0M $-48.0M $-58.0M $-71.0M $-92.0M Investing Cash Flow $-118.0M $42.0M $-6.0M $-107.0M $134.0M Financing Cash Flow $0 $1.0M $13.0M $0 $1.0M Net Cash Flow $-3.0M $-5.0M $10.0M $2.0M $-14.0M Free Cash Flow $-37.0M $-49.0M $-58.0M $-71.0M $-92.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.12 EV / EBITDA -2.73 FCF Yield -35.61% Quick Ratio 3.56 Interest Coverage 18.72 Return 1Y — Return 3Y — Return 5Y —
Screens featuring this stock